Editas Medicine (EDIT) Shares Outstanding (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Shares Outstanding data on file, last reported at $97.9 million in Q4 2025.

• Quarterly Shares Outstanding rose 18.29% year-over-year to $97.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $97.9 million (up 18.29% YoY) and the FY2025 annual result came in at $97.9 million, up 18.29% from the prior year.
• Shares Outstanding improved to $97.9 million in Q4 2025 per EDIT's latest filing, from $93.3 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $97.9 million in Q4 2025 and bottomed at $67.5 million in Q1 2021.
• The 5-year median for Shares Outstanding is $81.6 million (2023), against an average of $77.7 million.
• The widest annual swing landed in 2021, when Shares Outstanding increased 23.12%; it then rose 0.57% in 2023.
• Tracing EDIT's Shares Outstanding over 5 years: stood at $68.4 million in 2021, then increased by 0.6% to $68.8 million in 2022, then advanced by 18.77% to $81.8 million in 2023, then rose by 1.18% to $82.7 million in 2024, then increased by 18.29% to $97.9 million in 2025.
• Per Business Quant, the three latest EDIT Shares Outstanding figures stand at $97.9 million (Q4 2025), $93.3 million (Q3 2025), and $87.4 million (Q2 2025).

Peer Comparison